MedTrace Logo

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

NCT02432235 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2021-07-13

Study results available
· View outcomes & findings →

Summary

This study evaluates camidanlumab tesirine in participants with relapsed/refractory Non-Hodgkin or Hodgkin lymphoma.

Conditions

Interventions

DRUG

Camidanlumab tesirine

Intravenous (IV) infusion.

Sponsors & Collaborators

  • ADC Therapeutics S.A.

    lead INDUSTRY

Principal Investigators

  • Jens Wuerthner, MD, PhD · ADC Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-05
Primary Completion
2019-10-24
Completion
2019-10-24

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02432235 on ClinicalTrials.gov